deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03643965

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

Sponsor: Calliditas Therapeutics AB

Conditions Primary IgA Nephropathy
Interventions Nefecon Placebo oral capsule
Updated 14 times since 2018 Last updated: Nov 25, 2024 Started: Sep 5, 2018 Primary completion: Jul 10, 2023 Completion: Jul 10, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary IgA Nephropathy and is currently completed. Calliditas Therapeutics AB leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2018 – ~Jun 2019 · 9 months · monthly snapshot~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Mar 2023 · 14 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

14 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Jan 2025 — Sep 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Mar 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  8. Jun 2019 — Aug 2020 [monthly]

    Recruiting PHASE3

  9. Sep 2018 — Jun 2019 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calliditas Therapeutics AB
Data source: Calliditas Therapeutics AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Adana, Turkey (Türkiye) , Adelaide, Australia , Alcorcón, Spain , Asheville, United States , Athens, Greece , Aurora, United States , Barcelona, Spain , Bari, Italy , Belfast, United Kingdom and 117 more locations